NCT01226589

Brief Summary

Adverse drug events can occur commonly due to medication errors during the transition of care in a health care facility. Medication reconciliation is the process of comparing medications and providing an accurate medication list as a resource for prescribers, which is currently only being done upon inpatient admission at the CCI. The purpose of this study is to see if pharmacist medication reconciliation at discharge reduces unintentional medication discrepancies for inpatient discharges.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
50

participants targeted

Target at P25-P50 for not_applicable

Timeline
Completed

Started Oct 2007

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

October 1, 2007

Completed
1 year until next milestone

Study Completion

Last participant's last visit for all outcomes

October 1, 2008

Completed
2.1 years until next milestone

First Submitted

Initial submission to the registry

October 21, 2010

Completed
1 day until next milestone

First Posted

Study publicly available on registry

October 22, 2010

Completed
Last Updated

April 19, 2011

Status Verified

April 1, 2011

First QC Date

October 21, 2010

Last Update Submit

April 18, 2011

Conditions

Medication Reconciliation

Keywords

Cancer cancerMRSTreatment responseHistologically confirmed diagnosed Breast cancer.Patient is 18 years or older.Karnofsky performance score is equal to or greater than 70.No previously irradiated or recurrent breast.No contraindication to MRS/MRI.

Outcome Measures

Primary Outcomes (1)

  • MRS Correlation with Treatment Response.

    The percentage of patients with at least one unintentional medication discrepancy after discharge from the Cross Cancer Institute

    up to 1 year

Secondary Outcomes (2)

  • Correlation with Tumor Stage

    up to 1 year

  • The frequency of each type of unintentional medication discrepancies.

Interventions

MRSPROCEDURE

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Cancer inpatients under the care of Dr. Follett or Dr. Candler
  • Cancer inpatients to be discharged from the CCI
  • Patients \>18 years of age
  • Patients that are taking \>1 medications or herbals total at home.

You may not qualify if:

  • Cancer inpatients that are considered radioactive or in "hot rooms" (ie. Selectron patients or patients receiving radiation treatment for thyroid)
  • Patients that do not remain in hospital \>72 hours
  • Patients without a home phone number or equivalent contact number.
  • Language barrier (patients unable to speak or understand English).
  • Patients that are readmitted and already included into the study.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Cross Cancer Institute

Edmonton, Alberta, T6G 1Z2, Canada

Location

MeSH Terms

Conditions

Neoplasms

Study Officials

  • Carole Chambers, BSc. Pharmacy

    AHS Cancer Control Alberta

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
SINGLE GROUP
Sponsor Type
OTHER

Study Record Dates

First Submitted

October 21, 2010

First Posted

October 22, 2010

Study Start

October 1, 2007

Study Completion

October 1, 2008

Last Updated

April 19, 2011

Record last verified: 2011-04

Locations

CA(1)